Bionano Genomics (NASDAQ:BNGO) Shares Set to Reverse Split on Monday, January 27th

Bionano Genomics, Inc. (NASDAQ:BNGO) shares are scheduled to reverse split on the morning of Monday, January 27th. The 1-60 reverse split was announced on Wednesday, January 22nd. The number of shares owned by shareholders will be adjusted after the closing bell on Friday, January 24th.

Bionano Genomics Price Performance

Shares of NASDAQ:BNGO traded down $0.05 during midday trading on Thursday, hitting $0.13. The company’s stock had a trading volume of 31,894,418 shares, compared to its average volume of 19,639,521. The company has a debt-to-equity ratio of 0.07, a quick ratio of 0.99 and a current ratio of 1.43. The business’s 50 day simple moving average is $0.23 and its 200 day simple moving average is $0.37. Bionano Genomics has a 12-month low of $0.13 and a 12-month high of $1.36. The company has a market cap of $15.47 million, a P/E ratio of -0.06 and a beta of 2.22.

Analyst Ratings Changes

Separately, LADENBURG THALM/SH SH cut Bionano Genomics from a “buy” rating to a “neutral” rating in a report on Friday, November 15th.

Institutional Investors Weigh In On Bionano Genomics

Large investors have recently bought and sold shares of the stock. Carret Asset Management LLC lifted its position in shares of Bionano Genomics by 89.0% during the 3rd quarter. Carret Asset Management LLC now owns 85,055 shares of the company’s stock worth $39,000 after buying an additional 40,055 shares during the last quarter. GSA Capital Partners LLP acquired a new stake in Bionano Genomics during the 3rd quarter worth $46,000. Geode Capital Management LLC lifted its position in Bionano Genomics by 47.3% in the third quarter. Geode Capital Management LLC now owns 882,854 shares of the company’s stock valued at $401,000 after acquiring an additional 283,639 shares during the last quarter. Finally, Armistice Capital LLC acquired a new position in Bionano Genomics in the second quarter valued at $1,138,000. Hedge funds and other institutional investors own 11.35% of the company’s stock.

Bionano Genomics Company Profile

Bionano Genomics, Inc provides genome analysis software that enables genomics labs to analyze and interpret data across a range of platforms to generate informative data visualizations for streamlined and simple reporting of causal variants. It offers Saphyr, a sample-to-result solution for structural variation analysis by optical genome mapping for genome analysis and understanding of genetic variation and function; Saphyr instrument, a single-molecule imager; Saphyr Chip, a consumable that packages the nanochannel arrays for DNA linearization; and Bionano Prep Kits and DNA labeling kits, which provide the reagents and protocols for extracting and labeling ultra-high molecular weight DNA.